Research programme: vaccine development - Medicago/Mitsubishi Tanabe Pharma

Drug Profile

Research programme: vaccine development - Medicago/Mitsubishi Tanabe Pharma

Latest Information Update: 19 Sep 2013

Price : $50

At a glance

  • Originator Medicago
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rotavirus infections

Most Recent Events

  • 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
  • 30 Jun 2013 Medicago produces plant-based rotavirus VLP vaccine candidate containing all four structural antigens of rotavirus
  • 07 Mar 2012 Preclinical trials in Rotavirus infections in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top